Stock MBRX MOLECULIN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
5.15 USD +1.78% Intraday chart for Moleculin Biotech, Inc. +18.39% -60.00%
May. 01 Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman CI
Apr. 25 Transcript : Moleculin Biotech, Inc. - Special Call

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Ease in Afternoon Trading
MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU
MT
Top Premarket Decliners
MT
Moleculin Biotech Shares Rise Following Patent Announcement
MT
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
CI
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Moleculin Biotech to Effect 1-For-15 Reverse Stock Split to Regain Compliance
MT
Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
CI
Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
CI
Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
CI
Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
CI
Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials
CI
Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Moleculin Biotech, Inc. Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials
CI
Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
CI
Moleculin Biotech, Inc. Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia
CI
Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia
CI
Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBRX Stock
  4. News Moleculin Biotech, Inc.
  5. Highlights